CRISPR THERAPEUTICS AG Operating Lease Cost
CRISPR THERAPEUTICS AG (CRSP) reported Operating Lease Cost of $23.84 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-12
- CRISPR THERAPEUTICS AG operating lease, cost for the quarter ending 2019-12-31 was $2.21M.
- CRISPR THERAPEUTICS AG operating lease, cost for the quarter ending 2019-09-30 was $2.13M.
- CRISPR THERAPEUTICS AG operating lease, cost for the quarter ending 2019-06-30 was $1.90M.
- CRISPR THERAPEUTICS AG operating lease, cost for the quarter ending 2019-03-31 was $1.82M.
- CRISPR THERAPEUTICS AG operating lease, cost for fiscal 2025 was $23.84M, a 2.35% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG operating lease, cost for fiscal 2024 was $24.42M, a 5.62% decline from fiscal 2023.
- CRISPR THERAPEUTICS AG operating lease, cost for fiscal 2023 was $25.87M, a 25.87% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG operating lease, cost for fiscal 2022 was $34.90M, a 54.96% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $23.84M 10-K · filed 2026-02-12 | |||
| 2024-12-31 | $24.42M 10-K · filed 2026-02-12 | |||
| 2023-12-31 | $25.87M 10-K · filed 2026-02-12 | |||
| 2022-12-31 | $34.90M 10-K · filed 2025-02-11 | |||
| 2021-12-31 | $22.52M 10-K · filed 2024-02-21 | |||
| 2020-12-31 | $14.34M 10-K · filed 2023-02-21 | |||
| 2019-12-31 | $2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $4.34M derived: sum of 2 quarters · filed 2022-02-15 | $6.25M derived: sum of 3 quarters · filed 2022-02-15 | $8.07M 10-K · filed 2022-02-15 |
| 2019-09-30 | $2.13M 10-Q · filed 2019-10-28 | $4.04M derived: sum of 2 quarters · filed 2019-10-28 | $5.86M 10-Q · filed 2019-10-28 | |
| 2019-06-30 | $1.90M 10-Q · filed 2019-07-29 | $3.73M 10-Q · filed 2019-07-29 | ||
| 2019-03-31 | $1.82M 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |